
Humacyte (HUMA) Stock Forecast & Price Target
Humacyte (HUMA) Analyst Ratings
Bulls say
Humacyte Inc. has demonstrated significant growth in product sales, with approximately 29 units sold in the latest quarter, a notable increase from 4 units in the previous quarter, indicating a strong upward trajectory in demand. The company has achieved 25 vascular access centers' approval for its Symvess product, expanding its presence to around 92 civilian hospitals, which reflects increasing clinician familiarity and confidence in its technology. Furthermore, positive outcomes from preclinical evaluations and expectations for non-dilutive financing opportunities enhance the company's financial stability and growth potential, reinforcing a favorable outlook for Humacyte's stock.
Bears say
Humacyte Inc faces several significant risks that contribute to a negative outlook on its stock, including potential delays in clinical trial enrollments and product development. The company is also exposed to regulatory risks, which could further hinder its ability to bring products to market in a timely manner, leading to slower commercialization than anticipated. Additionally, the need for additional capital may result in dilution for existing shareholders, compounding the financial challenges for the company.
This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.
Humacyte (HUMA) Analyst Forecast & Price Prediction
Start investing in Humacyte (HUMA)
Order type
Buy in
Order amount
Est. shares
0 shares